July 2018

  New ETAP-Lab studies on TEMISIS' drug candidate TEM1657 for Psoriasis   ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced psoriasis model. The output of these studies showed that TEM1657 brings remarkable effects on psoriasis: Higher efficacy compared to the reference molecule No side effects Oral administration, which is new for the psoriasis treatment The French biotech company “Temesis”, subsidiary of Plant Advanced Technologies, recently published a new press release to announce these new promising preclinical results on psoriasis with